Egrifta SV
Generic name:tesamorelin
Dosage form: kit
Drug class:Growth hormones
Medically reviewed by Drugs.com. Last updated on Nov 1, 2021.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Egrifta SV
Egrifta SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Limitations of Use:
- Long-term cardiovascular safety of Egrifta SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
- Egrifta SV is not indicated for weight loss management as it has a weight neutral effect.
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking Egrifta SV.
Egrifta SV Dosage and Administration
Dosage and Administration
- The dosage and administration recommendations in this prescribing information only apply to Egrifta SV (tesamorelin for injection) 2 mg per vial formulation. For dosage and administration recommendations for tesamorelin for injection 1 mg per vial formulation, see the EGRIFTA prescribing information. These two formulations and strengths have differences in the dosage, the number of vials required to prepare a dose, reconstitution instructions, and storage requirements.
- The dose of EGRIFTA SV is 1.4 mg, 0.35 mL of the reconstituted solution [see Dosage and Administration (2.2)], injected subcutaneously once daily.
- Inject Egrifta SV into the abdomen. Rotate injection sites to different areas of the abdomen [see Warnings and Precautions (5.5)]. Do not inject into scar tissue, bruises or the navel.
Reconstitution Procedure
- Instruct patients to read the Instructions for Use enclosed in the Egrifta SV Medication Box.
- Use only the diluent provided, Sterile Water for Injection, USP, to reconstitute Egrifta SV.
-
MEDICAL DEPARTMENTS
CardiologyPediatricsDiabetes CarePre-natal CareUltrasound Echocardiogram
